{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:40:02Z","timestamp":1739641202712,"version":"3.37.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89717-3","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:08:22Z","timestamp":1739639302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2"],"prefix":"10.1038","volume":"15","author":[{"given":"Kabita","family":"Pandey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin Shane M.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyeongin","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpan","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis","family":"Fields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kritika","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srujana","family":"Rayalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddappa N.","family":"Byrareddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Mody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashidharamurthy","family":"Taval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"89717_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03426-1","author":"NG Davies","year":"2021","unstructured":"Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature https:\/\/doi.org\/10.1038\/s41586-021-03426-1 (2021).","journal-title":"Nature"},{"key":"89717_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n579","volume":"372","author":"R Challen","year":"2021","unstructured":"Challen, R. et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012\/1: matched cohort study. BMJ 372, n579. https:\/\/doi.org\/10.1136\/bmj.n579 (2021).","journal-title":"BMJ"},{"key":"89717_CR3","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820002599","volume":"148","author":"P Majumdar","year":"2020","unstructured":"Majumdar, P. & Niyogi, S. ORF3a mutation associated with higher mortality rate in SARS-CoV-2 infection. Epidemiol. Infect. 148, e262. https:\/\/doi.org\/10.1017\/S0950268820002599 (2020).","journal-title":"Epidemiol. Infect."},{"key":"89717_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijid.2020.11.190","volume":"103","author":"BO Motayo","year":"2021","unstructured":"Motayo, B. O. et al. Evolution and genetic diversity of SARS-CoV-2 in Africa using whole genome sequences. Int. J. Infect. Dis. 103, 282\u2013287. https:\/\/doi.org\/10.1016\/j.ijid.2020.11.190 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"89717_CR5","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1016\/j.vaccine.2016.11.015","volume":"34","author":"M Doherty","year":"2016","unstructured":"Doherty, M. et al. Vaccination of special populations: Protecting the vulnerable. Vaccine 34, 6681\u20136690. https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.015 (2016).","journal-title":"Vaccine"},{"key":"89717_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/v14030640","author":"N Magazine","year":"2022","unstructured":"Magazine, N. et al. Mutations and evolution of the SARS-CoV-2 spike protein. Viruses https:\/\/doi.org\/10.3390\/v14030640 (2022).","journal-title":"Viruses"},{"key":"89717_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/HIV.S79956","volume":"7","author":"Z Lv","year":"2015","unstructured":"Lv, Z., Chu, Y. & Wang, Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS 7, 95\u2013104. https:\/\/doi.org\/10.2147\/HIV.S79956 (2015).","journal-title":"HIV AIDS"},{"key":"89717_CR8","doi-asserted-by":"publisher","first-page":"Doc08","DOI":"10.3205\/id000034","volume":"5","author":"P de Leuw","year":"2017","unstructured":"de Leuw, P. & Stephan, C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect. Dis. 5, Doc08. https:\/\/doi.org\/10.3205\/id000034 (2017).","journal-title":"GMS Infect. Dis."},{"key":"89717_CR9","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"K Anand","year":"2003","unstructured":"Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300, 1763\u20131767. https:\/\/doi.org\/10.1126\/science.1085658 (2003).","journal-title":"Science"},{"key":"89717_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s42003-020-01577-x","volume":"4","author":"V Mody","year":"2021","unstructured":"Mody, V. et al. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun. Biol. 4, 93. https:\/\/doi.org\/10.1038\/s42003-020-01577-x (2021).","journal-title":"Commun. Biol."},{"key":"89717_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1126\/science.abb7498","volume":"368","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779\u2013782. https:\/\/doi.org\/10.1126\/science.abb7498 (2020).","journal-title":"Science"},{"key":"89717_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2020.11.024","volume":"433","author":"R Arya","year":"2021","unstructured":"Arya, R. et al. Structural insights into SARS-CoV-2 proteins. J. Mol. Biol. 433, 166725. https:\/\/doi.org\/10.1016\/j.jmb.2020.11.024 (2021).","journal-title":"J. Mol. Biol."},{"key":"89717_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac180","author":"LD Saravolatz","year":"2022","unstructured":"Saravolatz, L. D., Depcinski, S. & Sharma, M. Molnupiravir and nirmatrelvir-ritonavir: oral COVID antiviral drugs. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciac180 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"89717_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593. https:\/\/doi.org\/10.1126\/science.abl4784 (2021).","journal-title":"Science"},{"key":"89717_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02404-21","volume":"66","author":"RL Atmar","year":"2022","unstructured":"Atmar, R. L. & Finch, N. New perspectives on antimicrobial agents: molnupiravir and nirmatrelvir\/ritonavir for treatment of COVID-19. Antimicrob. Agents Chemother. 66, e0240421. https:\/\/doi.org\/10.1128\/aac.02404-21 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"89717_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/infdis\/jiab247","volume":"224","author":"S Zhou","year":"2021","unstructured":"Zhou, S. et al. beta-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J. Infect. Dis. 224, 415\u2013419. https:\/\/doi.org\/10.1093\/infdis\/jiab247 (2021).","journal-title":"J. Infect. Dis."},{"key":"89717_CR17","doi-asserted-by":"publisher","first-page":"9161","DOI":"10.1038\/s41598-023-35907-w","volume":"13","author":"M Zmudzinski","year":"2023","unstructured":"Zmudzinski, M. et al. Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PL(pro) and M(pro) proteases, and nsp14 guanine N7-methyltransferase. Sci. Rep. 13, 9161. https:\/\/doi.org\/10.1038\/s41598-023-35907-w (2023).","journal-title":"Sci. Rep."},{"key":"89717_CR18","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1038\/s41598-021-83229-6","volume":"11","author":"E Weglarz-Tomczak","year":"2021","unstructured":"Weglarz-Tomczak, E. et al. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2. Sci. Rep. 11, 3640. https:\/\/doi.org\/10.1038\/s41598-021-83229-6 (2021).","journal-title":"Sci. Rep."},{"key":"89717_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.861209","volume":"10","author":"DJ Calleja","year":"2022","unstructured":"Calleja, D. J. et al. Insights into drug repurposing, as well as specificity and compound properties of piperidine-based SARS-CoV-2 PLpro inhibitors. Front. Chem. 10, 861209. https:\/\/doi.org\/10.3389\/fchem.2022.861209 (2022).","journal-title":"Front. Chem."},{"key":"89717_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13044","author":"S Mahmoudvand","year":"2021","unstructured":"Mahmoudvand, S. & Shokri, S. Interactions between SARS coronavirus 2 papain-like protease and immune system: a potential drug target for the treatment of COVID-19. Scand. J. Immunol. https:\/\/doi.org\/10.1111\/sji.13044 (2021).","journal-title":"Scand. J. Immunol."},{"key":"89717_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000503030","volume":"12","author":"M Kikkert","year":"2020","unstructured":"Kikkert, M. Innate immune evasion by human respiratory RNA viruses. J. Innate Immun. 12, 4\u201320. https:\/\/doi.org\/10.1159\/000503030 (2020).","journal-title":"J. Innate Immun."},{"key":"89717_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41392-020-00335-z","volume":"5","author":"CB McClain","year":"2020","unstructured":"McClain, C. B. & Vabret, N. SARS-CoV-2: the many pros of targeting PLpro. Signal Transduct. Target Ther. 5, 223. https:\/\/doi.org\/10.1038\/s41392-020-00335-z (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"89717_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004113","volume":"10","author":"K Ratia","year":"2014","unstructured":"Ratia, K., Kilianski, A., Baez-Santos, Y. M., Baker, S. C. & Mesecar, A. Structural basis for the ubiquitin-linkage specificity and deISGylating activity of SARS-CoV papain-like protease. PLoS Pathog. 10, e1004113. https:\/\/doi.org\/10.1371\/journal.ppat.1004113 (2014).","journal-title":"PLoS Pathog."},{"key":"89717_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.bbadis.2010.02.006","volume":"1802","author":"YJ Jeon","year":"2010","unstructured":"Jeon, Y. J., Yoo, H. M. & Chung, C. H. ISG15 and immune diseases. Biochim. Biophys. Acta 1802, 485\u2013496. https:\/\/doi.org\/10.1016\/j.bbadis.2010.02.006 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"89717_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657\u2013662. https:\/\/doi.org\/10.1038\/s41586-020-2601-5 (2020).","journal-title":"Nature"},{"key":"89717_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","volume":"6","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target Ther. 6, 255. https:\/\/doi.org\/10.1038\/s41392-021-00679-0 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"89717_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41232-020-00146-3","volume":"40","author":"S Hojyo","year":"2020","unstructured":"Hojyo, S. et al. How COVID-19 induces cytokine storm with high mortality. Inflamm. Regen. 40, 37. https:\/\/doi.org\/10.1186\/s41232-020-00146-3 (2020).","journal-title":"Inflamm. Regen."},{"key":"89717_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109133","volume":"35","author":"K Bafna","year":"2021","unstructured":"Bafna, K. et al. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. Cell Rep. 35, 109133. https:\/\/doi.org\/10.1016\/j.celrep.2021.109133 (2021).","journal-title":"Cell Rep."},{"key":"89717_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116011","volume":"264","author":"P Jadhav","year":"2024","unstructured":"Jadhav, P. et al. Structure-based design of SARS-CoV-2 papain-like protease inhibitors. Eur. J. Med. Chem. 264, 116011. https:\/\/doi.org\/10.1016\/j.ejmech.2023.116011 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"89717_CR30","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41467-023-37254-w","volume":"14","author":"BC Sanders","year":"2023","unstructured":"Sanders, B. C. et al. Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2. Nat. Commun. 14, 1733. https:\/\/doi.org\/10.1038\/s41467-023-37254-w (2023).","journal-title":"Nat. Commun."},{"key":"89717_CR31","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1126\/science.adm9724","volume":"383","author":"B Tan","year":"2024","unstructured":"Tan, B. et al. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science 383, 1434\u20131440. https:\/\/doi.org\/10.1126\/science.adm9724 (2024).","journal-title":"Science"},{"key":"89717_CR32","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","volume":"65","author":"H Tan","year":"2022","unstructured":"Tan, H., Hu, Y., Jadhav, P., Tan, B. & Wang, J. Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J. Med. Chem. 65, 7561\u20137580. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00303 (2022).","journal-title":"J. Med. Chem."},{"key":"89717_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300216","volume":"18","author":"CS Brian Chia","year":"2023","unstructured":"Brian Chia, C. S. & Pheng Lim, S. A patent review on SARS coronavirus papain-like protease (PL(pro) ) inhibitors. ChemMedChem 18, e202300216. https:\/\/doi.org\/10.1002\/cmdc.202300216 (2023).","journal-title":"ChemMedChem"},{"key":"89717_CR34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","volume":"12","author":"Z Fu","year":"2021","unstructured":"Fu, Z. et al. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. Nat. Commun. 12, 488. https:\/\/doi.org\/10.1038\/s41467-020-20718-8 (2021).","journal-title":"Nat. Commun."},{"key":"89717_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26041134","author":"R Hajbabaie","year":"2021","unstructured":"Hajbabaie, R., Harper, M. T. & Rahman, T. Establishing an analogue based in silico pipeline in the pursuit of novel inhibitory scaffolds against the SARS coronavirus 2 papain-like protease. Molecules https:\/\/doi.org\/10.3390\/molecules26041134 (2021).","journal-title":"Molecules"},{"key":"89717_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25215064","author":"M Gendrot","year":"2020","unstructured":"Gendrot, M. et al. In vitro antiviral activity of doxycycline against SARS-CoV-2. Molecules https:\/\/doi.org\/10.3390\/molecules25215064 (2020).","journal-title":"Molecules"},{"key":"89717_CR37","unstructured":"FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning, https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline (2010)."},{"key":"89717_CR38","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41598-022-06104-y","volume":"12","author":"DSM Lewis","year":"2022","unstructured":"Lewis, D. S. M. et al. Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro. Sci. Rep. 12, 2145. https:\/\/doi.org\/10.1038\/s41598-022-06104-y (2022).","journal-title":"Sci. Rep."},{"key":"89717_CR39","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","volume":"12","author":"J Osipiuk","year":"2021","unstructured":"Osipiuk, J. et al. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat. Commun. 12, 743. https:\/\/doi.org\/10.1038\/s41467-021-21060-3 (2021).","journal-title":"Nat. Commun."},{"key":"89717_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01437-21","volume":"95","author":"A Acharya","year":"2021","unstructured":"Acharya, A. et al. Discovery and evaluation of entry inhibitors for SARS-CoV-2 and its emerging variants. J. Virol. 95, e0143721. https:\/\/doi.org\/10.1128\/JVI.01437-21 (2021).","journal-title":"J. Virol."},{"key":"89717_CR41","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/1947601912440575","volume":"2","author":"RJ Tallarida","year":"2011","unstructured":"Tallarida, R. J. Quantitative methods for assessing drug synergism. Genes Cancer 2, 1003\u20131008. https:\/\/doi.org\/10.1177\/1947601912440575 (2011).","journal-title":"Genes Cancer"},{"key":"89717_CR42","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 13, 504\u2013513. https:\/\/doi.org\/10.1016\/j.csbj.2015.09.001 (2015).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"89717_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.806","volume":"12","author":"A Acharya","year":"2022","unstructured":"Acharya, A. et al. PI3K-alpha\/mTOR\/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron. Clin. Transl. Med. 12, e806. https:\/\/doi.org\/10.1002\/ctm2.806 (2022).","journal-title":"Clin. Transl. Med."},{"key":"89717_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27\u201355. https:\/\/doi.org\/10.1016\/0065-2571(84)90007-4 (1984).","journal-title":"Adv. Enzyme Regul."},{"key":"89717_CR45","unstructured":"Chou T, M. N. CompuSyn software. CompuSyn for drug combinations: PC software and user\u2019s guide: a computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values. https:\/\/www.combosyn.com (ComboSyn Inc., 2005)."},{"key":"89717_CR46","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106275","volume":"39","author":"T Klemm","year":"2020","unstructured":"Klemm, T. et al. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO J. 39, e106275. https:\/\/doi.org\/10.15252\/embj.2020106275 (2020).","journal-title":"EMBO J."},{"key":"89717_CR47","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","volume":"65","author":"I Chopra","year":"2001","unstructured":"Chopra, I. & Roberts, M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65, 232\u2013260. https:\/\/doi.org\/10.1128\/MMBR.65.2.232-260.2001 (2001).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"89717_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00705-020-04860-8","volume":"166","author":"JA Mosquera-Sulbaran","year":"2021","unstructured":"Mosquera-Sulbaran, J. A. & Hernandez-Fonseca, H. Tetracycline and viruses: a possible treatment for COVID-19?. Arch. Virol. 166, 1\u20137. https:\/\/doi.org\/10.1007\/s00705-020-04860-8 (2021).","journal-title":"Arch. Virol."},{"key":"89717_CR49","doi-asserted-by":"publisher","first-page":"9955105","DOI":"10.1155\/2023\/9955105","volume":"2023","author":"Y Han","year":"2023","unstructured":"Han, Y. et al. In silico screening, in vitro mpro inhibitory, and adjunctive therapy value of minocycline for the treatment of COVID-19. J. Clin. Pharm. Ther. 2023, 9955105. https:\/\/doi.org\/10.1155\/2023\/9955105 (2023).","journal-title":"J. Clin. Pharm. Ther."},{"key":"89717_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.phrs.2012.10.006","volume":"67","author":"N Garrido-Mesa","year":"2013","unstructured":"Garrido-Mesa, N., Zarzuelo, A. & Galvez, J. What is behind the non-antibiotic properties of minocycline?. Pharmacol. Res. 67, 18\u201330. https:\/\/doi.org\/10.1016\/j.phrs.2012.10.006 (2013).","journal-title":"Pharmacol. Res."},{"key":"89717_CR51","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","volume":"26","author":"ZA Shyr","year":"2021","unstructured":"Shyr, Z. A., Cheng, Y. S., Lo, D. C. & Zheng, W. Drug combination therapy for emerging viral diseases. Drug Discov. Today 26, 2367\u20132376. https:\/\/doi.org\/10.1016\/j.drudis.2021.05.008 (2021).","journal-title":"Drug Discov. Today"},{"key":"89717_CR52","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1038\/s41564-023-01501-z","volume":"8","author":"LJM Bruurs","year":"2023","unstructured":"Bruurs, L. J. M. et al. Antiviral responses are shaped by heterogeneity in viral replication dynamics. Nat. Microbiol. 8, 2115\u20132129. https:\/\/doi.org\/10.1038\/s41564-023-01501-z (2023).","journal-title":"Nat. Microbiol."},{"key":"89717_CR53","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 20: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48, W488\u2013W493. https:\/\/doi.org\/10.1093\/nar\/gkaa216 (2020).","journal-title":"Nucleic Acids Res."},{"key":"89717_CR54","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202002.0418.v2","author":"S Talluri","year":"2020","unstructured":"Talluri, S. Virtual screening based prediction of potential drugs for COVID-19. Pharmacol. Toxicol. https:\/\/doi.org\/10.20944\/preprints202002.0418.v2 (2020).","journal-title":"Pharmacol. Toxicol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89717-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89717-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:08:26Z","timestamp":1739639306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89717-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89717"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89717-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5671"}}